InsightsHealthcare & Pharma

In 2001, Cipla priced a year of HIV treatment at $350.

By Uttam Dinodia2 min readView this post on LinkedIn

Five months earlier, its offer at $800 had found no takers.

In September 2000, Cipla's chairman Yusuf Hamied had three minutes at a European Union meeting. He offered the three-drug combination at $800 a year, against about $10,000 in the United States. His account: "I was so disappointed, there were no takers and nobody wrote to us."

In February 2001 the offer changed shape. Médecins Sans Frontières became the buyer at $350 a year, governments were quoted $600, and the New York Times headline read "Indian Company Offers AIDS Cocktail at a Dollar a Day". The chemistry was the same as in September. The price per day, the named buyer and the public promise were new.

Replay the choice. Cipla could have kept the $800 offer open and waited. It could have negotiated quietly, country by country, as the UN access scheme did. It chose a published price, a buyer whose word carried weight, and a unit anyone could hold in their head.

The textbook ran the other way. In 2003, Patricia Danzon and Adrian Towse argued that differential pricing survives only when discounts stay confidential, since published low prices invite reference pricing and parallel trade. Cipla published everything. An MSF review in 2011 concluded that "competition should generally be the default option" for affordability.

One caveat from the buyers' side. When PEPFAR began in 2003, its rules allowed only FDA-approved medicines, typically brands at 10 to 40 times the generic price, until a fast approval route for generics existed. A quoted price moves nothing until someone is allowed to pay it.

The combination now costs under $100 a year. UNAIDS counted 32.1 million people on treatment at the end of 2025.

Which offer in your market has a good price and still no first buyer?

Uttam Dinodia

Uttam Dinodia

Pharmaceutical Business Consultant & Executive Director, A One Afro Limited

Over 22 years in pharmaceutical supply. Helps international manufacturers and Zambian institutions with public tenders, ZAMRA regulatory pathways and distribution.